Document is current
Any future updates will be listed below
-
Authors
Linton, Samantha R.
Murphy, Michael
Schroder, Hans S.
Breiger, Micah
Iturra-Mena, Ann M.
Kangas, Brian D.
Bergman, Jack
Carlezon, William A. Jr
Risbrough, Victoria B.
Barnes, Samuel A.
Der-Avakian, Andre
Pizzagalli, Diego A.
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (UH2 MH109334, UH3 MH109334, R01MH063266)
U.S. Department of Defense (W81XWH-18-1-0761)
- License Information
-
More Information
Article History
Received: 30 December 2021
Accepted: 15 April 2022
First Online: 26 April 2022
Declarations
:
: Over the past 3 years, Dr. Pizzagalli has received consulting fees from Albright Stonebridge Group, Neumora Therapeutics (former BlackThorn Therapeutics), Boehringer Ingelheim, Compass Pathways, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Neuroscience Software, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; honoraria from the Psychonomic Society (for editorial work) and Alkermes; and research funding from NIMH, Dana Foundation, Brain and Behavior Research Foundation, Millennium Pharmaceuticals. In addition, he has received stock options from Neumora Therapeutics (former BlackThorn Therapeutics), Compass Pathways, Engrail Therapeutics, and Neuroscience Software. Over the past 3 years, Dr. Carlezon has received consulting fees from Psy Therapeutics. Dr. Der-Avakian holds equity ownership in PAASP US. Dr. Risbrough has received consulting fees from Engrail and Farallon Capital. Except for NIMH, no funding from these entities was used to support the work presented in this manuscript. All views expressed are solely those of the authors. All other authors confirm they have no disclosures to make in association with the work presented in this manuscript.
